Ascidian Therapeutics is a biotechnology company based in Boston, Massachusetts, developing RNA exon editing therapies for serious human diseases. The company was founded on the premise that rewriting RNA rather than DNA can address large genetic targets while avoiding permanent changes to the genome.
Ascidian applies its RNA exon editing platform to inherited retinal disorders and neurological conditions, with a lead programme directed at ABCA4 retinopathy. The approach is designed to replace multiple mutated exons in a single therapeutic, which allows one product to serve patients carrying a wide range of mutations in the same gene.
The company has raised venture financing led by Apple Tree Partners and in 2024 entered a research collaboration with Roche covering the discovery and development of RNA exon editing therapeutics for neurological diseases. Ascidian was founded by Michael Ehlers, who served as President and Chief Executive Officer until July 2026 and continues as Chair of the Board of Directors.
Recent Leadership News
- Ascidian Therapeutics appoints Daniel Rosan President (21 July 2026)
Facts compiled by Executive Moves from publicly available news and press releases on 22 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Ascidian Therapeutics team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
